David Laplaud
YOU?
Author Swipe
View article: Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials
Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials Open
Background Clinically defined relapses are the traditional primary endpoint of randomized control trials (RCTs) in multiple sclerosis (MS), yet a substantial proportion lack new inflammatory lesions. Confirming relapses with brain and spin…
View article: Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study
Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study Open
Background Sharing information derived from individual patient data is restricted by regulatory frameworks due to privacy concerns. Generative artificial intelligence can generate shareable virtual patient populations as proxies for sensit…
View article: Clonal analysis of SepSecS-specific CD4 T cells reveals a new HLA-DPA1*02:01/HLA-DPB1*01:01-restricted immunodominant epitope in autoimmune hepatitis
Clonal analysis of SepSecS-specific CD4 T cells reveals a new HLA-DPA1*02:01/HLA-DPB1*01:01-restricted immunodominant epitope in autoimmune hepatitis Open
Autoreactive CD4 T cells, recognizing liver-self-antigens such as SepSecS, are main drivers of the chronic inflammatory response during autoimmune hepatitis (AIH). Previous studies have uncovered immunodominant SepSecS epitopes often assoc…
View article: Intrathecal Anti-Akkermansia muciniphila IgG Responses in Multiple Sclerosis Patients Linked to CSF Immune Cells and Disease Activity
Intrathecal Anti-Akkermansia muciniphila IgG Responses in Multiple Sclerosis Patients Linked to CSF Immune Cells and Disease Activity Open
Background/Objectives: Gut microbial dysbiosis, leaky gut, and increased transepithelial translocation of commensal bacteria have been documented in multiple sclerosis (MS). Intrathecal IgGs specific for Akkermansia muciniphila, a gut bact…
View article: Durable B‐Cell Impairment While Sparing <scp>IgA</scp> B Cells After Ocrelizumab Therapy in Multiple Sclerosis
Durable B‐Cell Impairment While Sparing <span>IgA</span> B Cells After Ocrelizumab Therapy in Multiple Sclerosis Open
Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment…
View article: Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers
Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers Open
This study provides insightful information about the real-life indications for PE in French centers for the treatment of optic neuritis. Based on our findings and the available data in the literature, we provide a decision-making algorithm…
View article: Secondary progression activity monitoring in <scp>MS</scp> despite an early highly active treatment the <scp>SPAM</scp> study
Secondary progression activity monitoring in <span>MS</span> despite an early highly active treatment the <span>SPAM</span> study Open
Background Real‐world data suggest that the early use of highly active therapies (HAT) may reduce the risk of transition to secondary progressive MS (SPMS). However, current knowledge about predictive factors of outcomes needs to be improv…
View article: Genetic architecture of Multiple Sclerosis patients in the French national OFSEP-HD cohort
Genetic architecture of Multiple Sclerosis patients in the French national OFSEP-HD cohort Open
Multiple Sclerosis (MS) is a central nervous system (CNS) autoimmune inflammatory disease targeting the myelin sheath and affecting 2.8 million patients worldwide, mostly in economically advanced countries. The OFSEP-HD (French Multiple Sc…
View article: High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis Open
Importance Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting. Objective To evaluate the efficacy of high-dose …
View article: Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis Open
This study, using a 10-year clinical and administrative dataset, did not find any increased risk of relapse after IVF. The maintenance of disease-modifying therapies until IVF was a determining factor in reducing the risk of relapse.
View article: Intrathecal Anti-<i>Akkermansia muciniphila</i> IgG Responses in Multiple Sclerosis Patients linked to CSF Immune cells and Disease Activity
Intrathecal Anti-<i>Akkermansia muciniphila</i> IgG Responses in Multiple Sclerosis Patients linked to CSF Immune cells and Disease Activity Open
(1) Background: Gut microbial dysbiosis, leaky gut and increased transepithelial translocation of commensal bacteria have been documented in multiple sclerosis (MS). Intrathecal IgGs specific for Akkermansia muciniphila, a gut bacterium, a…
View article: Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution
Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution Open
Introduction Myeloid cells trafficking from the periphery to the central nervous system are key players in multiple sclerosis (MS) through antigen presentation, cytokine secretion and repair processes. Methods Combination of mass cytometry…
View article: Generation of synthetic gait data: application to multiple sclerosis patients' gait patterns
Generation of synthetic gait data: application to multiple sclerosis patients' gait patterns Open
Multiple sclerosis (MS) is the leading cause of severe non-traumatic disability in young adults and its incidence is increasing worldwide. The variability of gait impairment in MS necessitates the development of a non-invasive, sensitive, …
View article: Are we in a Big Data era for multiple sclerosis? Lessons from integrating clinical trials and observational studies data into the PRIMUS precision medicine platform
Are we in a Big Data era for multiple sclerosis? Lessons from integrating clinical trials and observational studies data into the PRIMUS precision medicine platform Open
Objective The “Projections In Multiple Sclerosis” (PRIMUS) project aims to develop a precision medicine platform enabling neurologists to support therapeutic decisions in multiple sclerosis by visualizing similar patient data among a refer…
View article: Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets
Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets Open
Sharing information provided by individual patient data is restricted by regulatory frameworks due to privacy concerns. Generative artificial intelligence could generate shareable virtual patient populations, as proxies of sensitive refere…
View article: Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets
Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets Open
Sharing information provided by individual patient data is restricted by regulatory frameworks due to privacy concerns. Generative artificial intelligence could generate shareable virtual patient populations, as proxies of sensitive refere…
View article: Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort
Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort Open
Introduction Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis. Its diagnosis is difficult as there is no specific test for it. Because of its rarity, the management of NS has so …
View article: Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy Open
S1P-RM-associated PML shows reduced IRIS risk but higher post-treatment MS activity. Clinicians should tailor post-PML treatment based on pre-PML medication.
View article: Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data
Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data Open
Background and purpose Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system, with numerous therapeutic options, but a lack of biomarkers to support a mechanistic approach to precision medicine. A computatio…
View article: Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study
Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study Open
In multiple sclerosis (MS), alterations of the gut microbiota lead to inflammation. However, the role of other microbiomes in the body in MS has not been fully elucidated. In a pilot case-controlled study, we carried out simultaneous chara…
View article: High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS Open
Importance A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-ef…
View article: Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis Open
Importance Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack …
View article: Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study
Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study Open
Background Eculizumab, a humanized monoclonal antibody targeting the C5 complement protein, has been approved for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody p…
View article: COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022 Open
Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset …
View article: 2367. Six-month Humoral Response Following Two Or Three Doses Of Covid-19 Vaccines As Primary Vaccination Followed Or Not By a Booster Dose In Specific Populations – ANRS0001S COV-POPART Cohort Study
2367. Six-month Humoral Response Following Two Or Three Doses Of Covid-19 Vaccines As Primary Vaccination Followed Or Not By a Booster Dose In Specific Populations – ANRS0001S COV-POPART Cohort Study Open
Background The duration of humoral response in immunocompromised populations according to the number of doses in the primary vaccine regimen and the number of booster doses is little known. Methods Participants from the French national mul…
View article: Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality
Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality Open
EMF has the great advantage of not requiring death certificates, their quality being less than optimal. Conceptually, it also seems more relevant because it avoids having to state, for each individual, whether death was directly or indirec…